Literature DB >> 9152383

Agonist-independent effect of an allosteric enhancer of the A1 adenosine receptor in CHO cells stably expressing the recombinant human A1 receptor.

C A Kollias-Baker1, J Ruble, M Jacobson, J K Harrison, M Ozeck, J C Shryock, L Belardinelli.   

Abstract

The allosteric enhancer PD 81,723, a 2-amino-3-benzoylthiophene derivative, has been shown to potentiate agonist binding to A1 adenosine receptors (A1AdoRs) and to enhance the functional effects of adenosine and adenosine analogs. The objective of this study was to determine whether the apparent agonist-independent effect of PD 81,723 observed in CHO cells stably expressing the recombinant human A1AdoR was due to the potentiation of the action of endogenous adenosine, to the presence of constitutive receptor activity and/or to the binding of PD 81,723 to the agonist binding site of the A1AdoR. The allosteric enhancer PD 81,723, the A1AdoR agonist (R)-N6-(2-phenylisopropyl)adenosine and adenosine all significantly inhibited forskolin-stimulated cAMP accumulation in intact cells and increased [35S]-5'-(gamma-thio)triphosphate binding to cell membranes. The effects of adenosine on cAMP formation and [35S]-5'-(gamma-thio)triphosphate binding were attenuated by adenosine deaminase, but the effects of PD 81,723 were not. In the presence of ADA, the A1AdoR antagonist 8-cyclopentyl-1,3-dipropylxanthine increased forskolin-stimulated cAMP accumulation in cells expressing the recombinant human A1AdoR but not in nontransfected CHO cells. In binding experiments, the agonist (R)-N6-(2-phenylisopropyl)adenosine, but not PD 81,723, significantly displaced the specific binding of the A1AdoR agonist [3H]-N6-cyclohexyladenosine and the antagonist [3H]-8-cyclopentyl-1,3-dipropylxanthine. The results of this study demonstrate that in CHO cells stably expressing the recombinant human A1AdoR, the agonist-independent effect of PD 81,723 is not due to potentiation of the action of endogenous adenosine or mediated by the binding of the allosteric enhancer to the agonist binding site of the recombinant human A1AdoR. It is possible that these effects are due to potentiation of constitutive receptor activity by PD 81,723.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9152383

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation.

Authors:  Richard W Mercier; Ying Pei; Lakshmipathi Pandarinathan; David R Janero; Jing Zhang; Alexandros Makriyannis
Journal:  Chem Biol       Date:  2010-10-29

2.  The allosteric enhancer PD81,723 increases chimaeric A1/A2A adenosine receptor coupling with Gs.

Authors:  Samita Bhattacharya; Rebecca L Youkey; Kobina Ghartey; Matthew Leonard; Joel Linden; Amy L Tucker
Journal:  Biochem J       Date:  2006-05-15       Impact factor: 3.857

3.  Pharmacological characterization of a small-molecule agonist for the chemokine receptor CXCR3.

Authors:  D J Scholten; M Canals; M Wijtmans; S de Munnik; P Nguyen; D Verzijl; I J P de Esch; H F Vischer; M J Smit; R Leurs
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 4.  Drugs for allosteric sites on receptors.

Authors:  Cody J Wenthur; Patrick R Gentry; Thomas P Mathews; Craig W Lindsley
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013-10-02       Impact factor: 13.820

5.  Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107.

Authors:  Ramachandran Murali; Xin Cheng; Alan Berezov; Xiulian Du; Arnie Schön; Ernesto Freire; Xiaowei Xu; Youhai H Chen; Mark I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-25       Impact factor: 11.205

Review 6.  Allosteric modulation of purine and pyrimidine receptors.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao; Anikó Göblyös; Adriaan P Ijzerman
Journal:  Adv Pharmacol       Date:  2011

7.  Allosteric modulation, thermodynamics and binding to wild-type and mutant (T277A) adenosine A1 receptors of LUF5831, a novel nonadenosine-like agonist.

Authors:  Laura H Heitman; Thea Mulder-Krieger; Ronald F Spanjersberg; Jacobien K von Frijtag Drabbe Künzel; Alessandro Dalpiaz; Adriaan P IJzerman
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

Review 8.  Allosteric modulation of the adenosine family of receptors.

Authors:  Zhan-Guo Gao; Soo-Kyung Kim; Adriaan P Ijzerman; Kenneth A Jacobson
Journal:  Mini Rev Med Chem       Date:  2005-06       Impact factor: 3.862

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.